Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
YCBD
cbdMD, Inc.
CAPPED RATING
cbdMD, Inc. (YCBD) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Revisions (F). The rating has held at C- for 5 weeks.
Quantitative Factor Evaluation • Updated
Overall Rating
2.1
/ 5.0
C-
Value
B
Factor Score
3.4
/ 5.0
Growth
C+
Factor Score
2.7
/ 5.0
Profitability
C+
Factor Score
2.6
/ 5.0
Momentum
D+
Factor Score
1.7
/ 5.0
Revisions
F
Factor Score
0.0
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
1.6
EV / EBITDA
-2.3
Rev Growth YoY
20.6%
Gross Margin
57.7%
Price Return 3M
-21.3%
Price Return 12M
-51.7%
Catalyst Signal
0.00
Market Cap
$5.0M
TTM Revenue
$20.9M
Price / Sales
0.2
ROE
-40.3%
Historical Factor Score Progression
Held C- for 5 weeks
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B (3.4) | C+ (2.7) | C+ (2.6) | D+ (1.7) | F (0.0) | C- (2.1) |
| 2026-11-08 | B (3.4) | C+ (2.8) | C+ (2.6) | D+ (1.5) | F (0.0) | C- (2.1) |
| 2026-11-01 | B (3.4) | C+ (2.7) | C+ (2.6) | D (1.4) | F (0.0) | C- (2.1) |
| 2026-10-25 | B (3.4) | C+ (2.7) | C+ (2.6) | D (1.3) | F (0.0) | C- (2.0) |
| 2026-10-18 | B (3.4) | C+ (2.7) | C+ (2.6) | D (1.4) | F (0.0) | C- (2.0) |
Page
1
of
3